Physician profile
Preethi Sriram
NPI 1093078222
$1,493.06
in general payments reported to CMS, 2019-2025
21 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $132 · 2021: $21.80 · 2022: $73.32 · 2023: $336 · 2024: $321 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $281.14 | 2019-2025 | Korlym |
| Dexcom, INC. | $200.65 | 2019-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $135.38 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $130.76 | 2019-2024 | Mounjaro, Jardiance |
| Abbvie INC. | $99.71 | 2019-2024 | |
| Novo Nordisk INC | $99.68 | 2019-2020 | |
| Beta Bionics, INC. | $98.24 | 2023 | Ilet Bionic Pancreas |
| Abbott Laboratories | $87.11 | 2019-2024 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.76 | 2019-2020 | |
| Valeritas, INC. | $48.11 | 2019 | |
| Mannkind Corporation | $43.36 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.22 | 2019 | |
| Medtronic, INC. | $33.25 | 2023 | Minimed 780g |
| Insulet Corporation | $18.80 | 2022 | |
| Radius Health, INC. | $18.77 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.66 | 2020 | |
| Horizon Therapeutics Plc | $15.65 | 2020 | |
| Amgen INC. | $14.52 | 2024 | Tepezza |
| Becton, Dickinson and Company | $14.04 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Sriram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.